LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been assigned an average recommendation of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $112.60.

Several analysts have commented on the company. Citizens Jmp lifted their price target on LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a report on Wednesday, May 6th. Wall Street Zen upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Zacks Research upgraded LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a report on Monday, April 13th. Wells Fargo & Company boosted their target price on LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Finally, Weiss Ratings upgraded LeMaitre Vascular from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday.

LeMaitre Vascular Trading Down 1.8%

LeMaitre Vascular stock opened at $97.75 on Monday. The stock has a market cap of $2.23 billion, a PE ratio of 36.07, a P/E/G ratio of 2.76 and a beta of 0.60. The stock has a 50-day moving average price of $108.54 and a 200 day moving average price of $95.31. LeMaitre Vascular has a 52 week low of $78.35 and a 52 week high of $118.01. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.02. The firm had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.48 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Equities research analysts predict that LeMaitre Vascular will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Thursday, May 21st will be issued a dividend of $0.25 per share. The ex-dividend date is Thursday, May 21st. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.0%. LeMaitre Vascular’s payout ratio is presently 36.90%.

Insider Transactions at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,928 shares of the business’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $107.00, for a total transaction of $313,296.00. Following the completion of the sale, the insider owned 3,749 shares in the company, valued at approximately $401,143. The trade was a 43.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO George W. Lemaitre sold 27,881 shares of the business’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the sale, the chief executive officer owned 1,430,019 shares of the company’s stock, valued at $155,428,765.11. The trade was a 1.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 269,891 shares of company stock worth $28,969,086 over the last 90 days. Company insiders own 7.40% of the company’s stock.

Institutional Trading of LeMaitre Vascular

A number of institutional investors have recently modified their holdings of the company. Illinois Municipal Retirement Fund grew its holdings in shares of LeMaitre Vascular by 1.1% during the 4th quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock worth $906,000 after purchasing an additional 123 shares during the period. NewEdge Advisors LLC lifted its position in LeMaitre Vascular by 4.6% during the 4th quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock worth $256,000 after acquiring an additional 139 shares in the last quarter. State of Alaska Department of Revenue lifted its position in LeMaitre Vascular by 1.2% during the 4th quarter. State of Alaska Department of Revenue now owns 11,986 shares of the medical instruments supplier’s stock worth $971,000 after acquiring an additional 147 shares in the last quarter. Johnson Investment Counsel Inc. lifted its position in LeMaitre Vascular by 0.5% during the 3rd quarter. Johnson Investment Counsel Inc. now owns 29,792 shares of the medical instruments supplier’s stock worth $2,607,000 after acquiring an additional 153 shares in the last quarter. Finally, Federated Hermes Inc. lifted its position in LeMaitre Vascular by 0.4% during the 2nd quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock worth $3,294,000 after acquiring an additional 155 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.